Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 11 of 25

TERMINATED NA

Expiratory Muscle Strength Training and Phonation Resistance Training Exercises For Elderly Patients With Vocal Fold Atrophy

NCT03696576
COMPLETED NA

Primary-Care Based Mindfulness Intervention

NCT03922581
COMPLETED Phase 4

Weight Loss Aid in an Exposed Population

NCT03582722
COMPLETED Phase 1

Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

NCT03507491
COMPLETED NA

Smartstep Smartphone PAD

NCT03479255
COMPLETED Phase 3

Vitamin C, Thiamine, and Steroids in Sepsis

NCT03509350
COMPLETED NA

Exercise is Medicine at Emory Seavey Internal Medicine Clinic

NCT03416634
COMPLETED NA

A Rigorous Evaluation of the Relationship Between Physical Activity and Education Outcomes

NCT03765047
TERMINATED NA

Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease

NCT03577691
COMPLETED NA

Human Milk for Congenital Gastrointestinal Disorders

NCT02567292
COMPLETED NA

Social Capital and Engagement in Care Among Young Black Men Who Have Sex With Men Living With HIV

NCT03664817
COMPLETED Phase 1

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

NCT03328104
COMPLETED Phase 4

Effect of Ketorolac on Post Adenotonsillectomy Pain

NCT03467750
COMPLETED Early Phase 1

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

NCT03529825
TERMINATED Phase 4

Paravertebral Nerve Blocks in Neonates

NCT03408340
COMPLETED Phase 4

Responses to Rabies Vaccine in Adults With or Without Antibiotics

NCT03557008
COMPLETED Phase 2

A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder

NCT03008889
COMPLETED NA

CBCT for Spiritual Health Clinicians

NCT03529812
COMPLETED NA

Faith-Based African American Cancer Survivorship Storytelling

NCT03082612
COMPLETED Phase 2

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

NCT03521570
COMPLETED NA

Improving Health-Promoting Behaviors in Adolescent Cancer Survivors Using AWAKE: A Feasibility Trial

NCT03564587
COMPLETED NA

Meditation for Pain

NCT03495726
TERMINATED NA

MRI Guided Prostate Cancer Focal Laser Ablation

NCT03634579
COMPLETED Phase 1

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

NCT03267888
TERMINATED NA

Epidural Technique: Does it Really Matter to the Patient?

NCT03539796
COMPLETED NA

Preparation for End-of-Life Decision Making in Mild Dementia

NCT03311711
COMPLETED NA

Soccer-based Adaptation of the Diabetes Prevention Program

NCT03595384
COMPLETED Phase 1

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

NCT03472963
COMPLETED NA

Stress and CKD Among African Americans

NCT03387319
COMPLETED Phase 1

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

NCT03493789
TERMINATED Phase 1

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

NCT03270709
TERMINATED Phase 2

Gemcabene for the Treatment of Pediatric NAFLD

NCT03436420
COMPLETED NA

Innovative Gait Biofeedback Strategies for Stroke Rehabilitation

NCT03466372
TERMINATED NA

Improving Mitral Repair for Functional Mitral Regurgitation

NCT03366649
COMPLETED NA

Exercise and RP (AVAMC and Emory)

NCT03381235
COMPLETED Phase 2

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

NCT03448458
COMPLETED NA

An Effectiveness-Implementation Trial of SPIRIT in ESRD

NCT03138564
COMPLETED Early Phase 1

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
COMPLETED NA

Improving Infant Nutrition in Southern Ethiopia

NCT03423472
COMPLETED NA

Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families

NCT03307057
COMPLETED NA

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

NCT03666247
COMPLETED NA

Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors

NCT03187275
COMPLETED NA

CBT for African Americans With Cognitive Impairment

NCT03384069
COMPLETED NA

Cryoablation for Post Mastectomy Pain Syndrome

NCT03293940
TERMINATED Phase 2

A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)

NCT03060772
COMPLETED Phase 4

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NCT03336528
COMPLETED NA

Glucose Measurement Using Microneedle Patches

NCT02682056
COMPLETED Phase 1

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

NCT03373188
COMPLETED NA

iEAT 2.0 Open Trial

NCT03383029
COMPLETED NA

A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes

NCT03224234
← Previous Page 11 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

Therapeutic Areas

Depression 12
Breast Cancer 9
Sickle Cell Disease 9
Post Traumatic Stress Disorder 7
Diabetes 7
Coronary Artery Disease 6
Cystic Fibrosis 6
Hypertension 6
Stage IV Lung Cancer AJCC v8 6
Dementia 6

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.